Reporter: Aviva Lev-Ari, PhD, RN
DNA Methultransferases – Implications to Epigenetic Regulation and Cancer Therapy Targeting: James Shen, PhD
April 22, 2013 by 2012pharmaceutical
One Response
Leave a Reply
Follow Blog via Email
Join 2,041 other subscribers-
Recent Posts
- Novartis and Bristol Myers Squibb halt CAR-T trial for autoimmune diseases over patient deaths: a potential issue with cell-based manufacturing September 15, 2026
- FDA Contemplates Changes in Trial Design, Drug Development, and Use of AI in Clinical Trials September 15, 2026
- FDA Moves Forward With Its Guidance Framework for Rare Disease Trials: 2026 August 3, 2026
- Artificial Intelligence TRANSFORMS Medicine, Biotech and Healthcare, How? August 3, 2026
- In Memoriam: Nobel Laureate J. Michael Bishop for discovery of Retroviral Oncogenes July 31, 2026
- Companies Actively Engaging Artificial Intellegence for Drug Design: 2026 July 31, 2026
- AI-Native Drug Discovery Landscape 2026 – How LPBI Group Differentiates in the New Era of Foundation Models July 19, 2026
- In Memoriam: In Remembrance of Cancer Researchers who passed in 2026 July 13, 2026
- Urgent Request for Action on Proposed Rule Affecting Federal Funding Grant Review July 7, 2026
- 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy Revolutionizing Treatments for Blood Cancers and Solid Tumors July 5, 2026
Archives
Categories
Meta
2012pharmaceutical
sjwilliamspa
I actually consider this amazing blog , âSAME SCIENTIFIC IMPACT: Scientific Publishing –
Open Journals vs. Subscription-based « Pharmaceutical Intelligenceâ, very compelling plus the blog post ended up being a good read.
Many thanks,Annette